Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX as Neoadjuvant Chemotherapy for Advanced Gastric Cancer with PAN Metastasis
NCT02071043Phase 2Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Nov 2008
- Primary completion
- Jan 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capecitabine and oxaliplatin in gastric cancer (GC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective Response Rate at 8 months. Started Nov 2008; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02071043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02071043.